ArticleJournal of cachexia, sarcopenia and muscle2017
Myopenia and precision (P4) medicine.
Article in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Ninjin'yoeito in the Management of Frailty and Overactive Bladder in Elderly Women: A Report of Two Cases.Cureus · 2024Article
- Proteomics and machine learning in the prediction and explanation of low pectoralis muscle area.Scientific reports · 2024Article
- Sequencing technology in sarcopenia: current research progress and future trends.Frontiers in molecular biosciences · 2024Article
- Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice.Irish journal of medical science · 2022Review
- Editorial: Resilience And Successful Aging.The journal of nutrition, health & aging · 2022Article
- Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021.Journal of cachexia, sarcopenia and muscle · 2021Article
- Sarcopenia: Diagnosis and Management, State of the Art and Contribution of Ultrasound.Journal of clinical medicine · 2021Review
- Editorial: The Future of Geriatrics.The journal of nutrition, health & aging · 2020Article
- Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine.International journal of general medicine · 2020Review
- Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019.Journal of cachexia, sarcopenia and muscle · 2019Article
- Predictive, Personalized, Preventive and Participatory (4P) Medicine Applied to Telemedicine and eHealth in the Literature.Journal of medical systems · 2019Review
- Editorial: Vitamin D: Does the Emperor Have No Clothes?The journal of nutrition, health & aging · 2019Article
- Senolytics: The Modern Snake Oil?The journal of nutrition, health & aging · 2019Article
- Editorial: Population Health and Aging.The journal of nutrition, health & aging · 2019Article
- Treatment of sarcopenia: the road to the future.Journal of cachexia, sarcopenia and muscle · 2018Article
- Muscle wasting and sarcopenia in heart failure: a brief overview of the current literature.ESC heart failure · 2018Article
- More variety with the Journal of Cachexia, Sarcopenia and Muscle: JCSM Clinical Reports and JCSM Rapid Communications have both gone live.Journal of cachexia, sarcopenia and muscle · 2018Article
- Editorial: Dysphagia, Dementia and Frailty.The journal of nutrition, health & aging · 2018Article
- Editorial: Frailty, Comorbidity, and COPD.The journal of nutrition, health & aging · 2018Article
- Myopenia and precision (P4) medicine.Journal of cachexia, sarcopenia and muscle · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision (P4) medicine represents a new medical paradigm that focuses on Personalized, Predictive, Preventive and Participatory approaches. The P4 paradigm is particularly appropriate for moving the care of persons with myopenia forward. Muscular dystrophies are clearly a set of genetically different diseases where genomics are the basis of diagnosis, and genetic modulation via DNA, oligonucleotides and clustered regularly interspaced short palendronic repeats hold great potential for a cure. The utility of personalized genomics for sarcopenia coupled with utilizing a predictive approach for the diagnosis with early preventive strategies is a key to improving sarcopenic outcomes. The importance of understanding different levels of patient enthusiasm and different responses to exercise should guide the participatory phase of sarcopenic treatment. In the case of cachexia, understanding the effects of the different therapies now available through the P4 approach on muscle wasting is a key to management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.